Quarterly report pursuant to Section 13 or 15(d)

Shareholders' Equity

v2.4.0.8
Shareholders' Equity
3 Months Ended
Mar. 31, 2014
Equity [Abstract]  
Shareholders' Equity

10. Shareholders’ Equity

Changes in shareholders’ equity for the three months ended March 31, 2014 were as follows (in thousands):

 

Total shareholders’ equity as of December 31, 2013

   $ 551,446   

Net income

     74,628   

Issuance of common shares from exercise of stock options, SARs, restricted stock grants, and employee stock purchase plan

     60   

Excess tax benefit from exercise of stock options, SARs and restricted stock grants

     3,154   

Additional capital from share-based compensation

     10,995   

Repurchases of common shares, including Forward Transactions

     (694,503

Allocation to additional paid-in capital due to issuance of senior convertible notes and Forward Transactions.

     249,797   

Reduction in additional paid-in capital from purchased capped call

     (123,825

Dividends paid and received, net

     (26,955

Foreign currency translation adjustment, net of income taxes

     (2,183

Unrealized loss on derivatives, net of income taxes

     (413

Unrealized loss on available-for-sale investments, net of income taxes

     (95
  

 

 

 

Total shareholders’ equity as of March 31, 2014

   $ 42,106   
  

 

 

 

 

Dividends

The declaration of future dividends is subject to the discretion of the Company’s board of directors and will depend upon various factors, including its earnings, financial condition, Herbalife Ltd.’s available distributable reserves under Cayman Islands law, restrictions imposed by the Credit Facility and the terms of any other indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by its board of directors. The Credit Facility permits payments of dividends as long as no default or event of default exists and the consolidated leverage ratio specified in the Credit Facility is not exceeded.

On February 18, 2014, the Company announced that its board of directors approved a cash dividend of $0.30 per common share in an aggregate amount of $30.4 million that was paid to shareholders on March 18, 2014. The aggregate total amount of dividends declared and paid during the three months ended March 31, 2014, and 2013, were $30.4 million and $30.9 million, respectively. During the three months ended March 31, 2014, the Company received $3.4 million of dividends primarily relating to the Forward Transactions described below which was recorded directly to its (accumulated deficit) retained earnings.

Share Repurchases

On July 30, 2012, the Company announced that its board of directors authorized a new $1 billion share repurchase program that will expire on June 30, 2017. On February 3, 2014, the Company announced that its board of directors authorized an increase in the existing share repurchase authorization to an available balance of $1.5 billion. This share repurchase program allows the Company to repurchase its common shares, at such times and prices as determined by the Company’s management as market conditions warrant, and to the extent Herbalife Ltd.’s distributable reserves are available under Cayman Islands law. The Credit Facility permits the Company to repurchase its common shares as long as no default or event of default exists and the consolidated leverage ratio specified in the Credit Facility is not exceeded.

In conjunction with the issuance of the Convertible Notes during February 2014, the Company paid approximately $685.8 million to enter into prepaid forward share repurchase transactions, or the Forward Transactions, with certain financial institutions, or Forward Counterparties, pursuant to which the Company purchased approximately 9.9 million common shares for settlement on or around the August 15, 2019 maturity date for the Convertible Notes, subject to the ability of each Forward Counterparty to elect to settle all or a portion of its Forward Transaction early. The Forward Transactions are generally expected to facilitate privately negotiated derivative transactions between the Forward Counterparties and holders of the Convertible Notes, including swaps, relating to the common shares by which holders of the Convertible Notes establish short positions relating to the common shares and otherwise hedge their investments in the Convertible Notes concurrently with, or shortly after, the pricing of the Convertible Notes. As a result of this transaction, the Company’s total shareholders’ equity within its consolidated balance sheet was reduced by approximately $685.8 million during the first quarter of 2014, with amounts of $653.9 million and $31.9 million being allocated between (accumulated deficit) retained earnings and additional paid-in-capital, respectively, within total shareholders’ equity. Also, upon executing the Forward Transactions, the Company recorded $35.8 million in non-cash issuance costs with a corresponding amount to additional paid-in-capital, reflecting the fair value of the Forward Transactions. The non-cash issuance costs will be amortized over the term of the Forward Transactions. For the three months ended March 31, 2014, the Company recognized $1.0 million of non-cash interest expense within its consolidated statement of income relating to amortization of these non-cash issuance costs.

As a result of the Forward Transaction, the Company had effectively purchased approximately 9.9 million common shares at an average cost of $69.02 per share which are treated as retired for basic and diluted EPS purposes although they remain legally outstanding. As of March 31, 2014, the remaining authorized capacity under the Company’s share repurchase program was $814.2 million and had been reduced as a result of the Forward Transactions.

The Company reflects the aggregate purchase price of its common shares repurchased as a reduction to shareholders’ equity. The Company allocated the purchase price of the repurchased shares to (accumulated deficit) retained earnings, common shares and additional paid-in-capital.

The number of shares issued upon vesting or exercise for certain restricted stock units and SARs granted pursuant to the Company’s share-based compensation plans is net of the minimum statutory withholding requirements that the Company pays on behalf of its employees. Although shares withheld are not issued, they are treated as common share repurchases in the Company’s consolidated financial statements, as they reduce the number of shares that would have been issued upon vesting. These shares do not count against the authorized capacity under the Company’s share repurchase program described above.

 

Capped Call Transactions

In connection with the issuance of Convertible Notes, the Company paid approximately $123.8 million to enter into capped call transactions with respect to its common shares, or the Capped Call Transactions, with certain financial institutions. The Capped Call Transactions are expected generally to reduce the potential dilution upon conversion of the Convertible Notes in the event that the market price of the common shares is greater than the strike price of the Capped Call Transactions, initially set at $86.28 per common share, with such reduction of potential dilution subject to a cap based on the cap price initially set at $120.79 per common share. The strike price and cap price are subject to certain adjustments under the terms of the Capped Call Transactions. Therefore, as a result of executing the Capped Call Transactions, the Company in effect will only be exposed to potential net dilution once the market price of its common shares exceeds $120.79. As a result of the Capped Call Transactions, the Company’s additional paid-in capital within shareholders’ equity on its consolidated balance sheet was reduced by $123.8 million during the first quarter of 2014.

Accumulated Other Comprehensive Income (Loss)

The following table summarizes changes in accumulated other comprehensive income (loss) during the three months ended March 31, 2014:

 

     Changes in Accumulated Other Comprehensive
Income (Loss) by Component
Three Months Ended March 31, 2014
 
     Foreign
Currency
Translation
Adjustments
    Unrealized
Gain (Loss) on
Derivatives
    Unrealized Gain
(Loss) on
Available-For-
Sale Investments
    Total  
     (In millions)  

Beginning Balance

   $ (25.6   $ 5.7      $ 0.1      $ (19.8
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss) before reclassifications, net of tax

     (2.2     (0.1     (2.1     (4.4

Amounts reclassified from accumulated other comprehensive income (loss) to income, net of tax(1)

     —          (0.3     2.0        1.7   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other comprehensive income (loss), net of reclassifications

     (2.2     (0.4     (0.1     (2.7
  

 

 

   

 

 

   

 

 

   

 

 

 

Ending balance

   $ (27.8   $ 5.3      $ —        $ (22.5
  

 

 

   

 

 

   

 

 

   

 

 

 

 

(1) See Note 2, Significant Accounting Policies, and Note 9, Derivative Instruments and Hedging Activities, for information regarding the location in the condensed consolidated statements of income of gains (losses) reclassified from accumulated other comprehensive income (loss) into income during the three months ended March 31, 2014.

Other comprehensive income (loss) before reclassifications was net of tax benefits of $0.1 million, $0.1 million, and $1.1 million for foreign currency translation adjustments, unrealized gain (loss) on derivatives, and unrealized gain (loss) on available-for-sale investments, respectively, for the three months ended March 31, 2014. Amounts reclassified from accumulated other comprehensive income (loss) to income was net of tax expense of $1.0 million for unrealized gain (loss) on available-for-sale investments for the three months ended March 31, 2014.